Solventum Corporation (SOLV) fair value analysis
S&P 500 · Updated 2026-10-19
SOLV price how computed
Forward Fair Value verdict
Fairly valuedSOLV is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $87.29
- Sector
- Healthcare
- 12-month range
- $62.49–$92.44
- Market cap
- $14.9B
- From 52-week high
- -5.6%
- Shares outstanding
- 170M
- Rank in Healthcare by discount to fair value
- #63 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Solventum Corporation is a healthcare company that develops, manufactures, and sells medical devices, software, and services for various healthcare applications. The company operates globally, serving customers across North America, Europe, Asia Pacific, and other international markets.
SOLV currently ranks #63 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 11 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $14.9B
- P/E (trailing)
- 12x
- Revenue (TTM)
- $8.31B
- Net margin
- 17.3%
- EPS (TTM)
- $7.10
- Gross margin
- 58.2%
- Debt / equity
- 1.10
- Revenue growth (3-yr avg)
- 2.2%
- Shares outstanding
- 170M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 44 · neutral
- 50-day average
- $88.43
- 200-day average
- $78.26
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+33.5%)
2026-03 ▲ beat (+9.6%)
2025-12 ▲ beat (+4.7%)
2025-09 ▲ beat (+4.9%)
2025-06 ▲ beat (+16.6%)
2025-03 ▲ beat (+9.8%)
2024-12 ▼ miss (-6.0%)
2024-09 ▲ beat (+18.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 5 hold · 2 sell (15 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $94.7
- Target vs last price
- +8.5%
What our data shows for SOLV
- Our model validated 8 trailing price-to-earnings windows for SOLV, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $62.49–$92.44.
- The 14-day relative strength index sits at a neutral 44.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for SOLV
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the SOLV conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — SOLV's sector positioning improved this week, with its sector discount rank moving from number 85 to number 80, indicating a stronger relative valuation position within the Healthcare sector. The company maintains a Fairly valued verdict according to TickrTrends' derived indicators.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is SOLV stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), SOLV is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is SOLV's TickrTrends verdict?
SOLV's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does SOLV compare to other Healthcare stocks?
SOLV ranks #63 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is SOLV overbought or oversold?
SOLV's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does SOLV report earnings next?
SOLV's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does SOLV usually beat earnings estimates?
Over its last 8 reported quarters SOLV beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SOLV?
Of 15 analysts covering SOLV, 8 rate it a buy, 5 a hold and 2 a sell - buy-leaning, with a consensus price target of $94.7 (+8.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
SOLV vs A · SOLV vs ABVX · SOLV vs AGMB · SOLV vs AVAH · SOLV vs BVS